[Translation] A multicenter, open-label, single-dose, ascending-dose phase I clinical trial of recombinant human truncated plasmin (JZB32) injection for the treatment of polypoidal choroidal vasculopathy
探索息肉样脉络膜血管病变(PCV)受试者玻璃体腔单次注射 JZB32 后的安全性,确定最大耐受剂量(MTD),及用于 II 期临床试验的推荐剂量(RP2D)
[Translation] To explore the safety of a single intravitreal injection of JZB32 in subjects with polypoidal choroidal vasculopathy (PCV), to determine the maximum tolerated dose (MTD), and the recommended dose for phase II clinical trials (RP2D)